Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morphotek initiates Phase II pancreatic cancer study
The randomized, controlled, double-blinded trial will compare MORAb-009 plus gemcitabine with a placebo plus gemcitabine. The primary objective of the study is to assess the efficacy of MORAb-009
The randomized, controlled, double-blinded trial will compare MORAb-009 plus gemcitabine with a placebo plus gemcitabine. The primary objective of the study is to assess the efficacy of MORAb-009
Under the terms of the agreement Osiris will immediately regain worldwide rights to its stem cell technology for all cardiovascular indications. In exchange, Osiris has agreed to relieve
The co-promotion will begin during the first quarter of 2008. Cephalexin, the generic form of Keflex, is said to be the number-one recommended oral antibiotic therapy for uncomplicated
The subjects in the Cethrin Phase I/IIa trial suffered a complete thoracic or cervical spinal cord injury (SCI) and were thus classified as an A on the American
The Empower study is a randomized, double-blind, placebo-controlled study and will include up to 220 patients across 15 clinical sites in the US and Australia. The company expects
The objective of the Phase IIb study is to compare the efficacy of PDX to that of Tarceva. The primary endpoint of the study is overall survival. Secondary
As part of the collaboration, the companies will apply the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX breast cancer test. Chu
The double-blind, placebo controlled trial, being conducted at 15 sites in the US, is a dose response study comparing 400mg and 600mg of Droxidopa to placebo in a
Rosetta Genomics has developed a custom designed, highly sensitive and specific microRNA detection platform which is based on Roche PCR technology. This proprietary platform is said to help
VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. The Phase II clinical program’s innovative trial